Quote:Whether this NBA is for all HIV isn't known either.
Good point. NP is impossible to read. He stated in the video today that BP (ViiV and GLD) are not interested in COMBO, but they are interested in MONO (which he has stated many times in the past).
And he also stated that they were in discussions with mid-tier pharma.
If the current NBA deal is with mid-tier pharma, then one would expect it is only for COMBO -- i.e. leaving the door open for BP for MONO. But $90M milestone payments is substantial for COMBO only and the mid-tier pharma company would certainly want MONO as well.
+++++
On a related note in response to a different post, it doesn't appear that NP used "upfront payment" when describing the deal.
Quote:29:16 program with sign a non-binding
29:19 agreement which is very solid agreement
29:25 as about $90M of milestones,
29:29 they pay $50M dollars of the
29:32 launching the product and after that
29:34 upon launching they continue to pay for it.
29:37 We get 50% of the royalty of the sales.
29:40 ThaiMed gets 52% of their sales.
29:44 percent of their technology so we also
29:48 get the cost of goods, plus 10%. Now
29:51 non-binding agreement was signed a few
29:54 weeks ago, they have six more weeks.
Therefore, I would guess that there is no payment due upon signing the agreement, which would lead to the likely first milestone being: a) (optimistically) filing part 2 of the BLA asap after Oct 31st when safety data is expected; or b) (most likely) when the full BLA is submitted which could be as late as Dec. 31st.
If it is "b", then we need to raise $10-15M more, which will almost certainly come in a similar form to all our recent raises (discount to ATM + warrants, or convertible debt), which is, IMO, raises at 90+% discount to where we should be raising money at this stage in the development of CYDY
1
